Background and aims

The purpose of this study is to examine patterns of utilization for antidiabetic medications among a nationally representative sample of the US population following the introduction of SGLT2 inhibitors in 2013.

Methods

The study utilized National Health and Nutrition Examination Survey (NHANES) data from 2013 to 2020 to identify adult patients with diabetes using antidiabetic medication. The proportion of patients with diabetes using different antidiabetic medications, including SGLT2 inhibitors, was plotted over time. To assess the statistical significance of the utilization trend of SGLT2 inhibitors and other oral antidiabetics, logistic regression models were employed.

Results

A weighted total of 26,421,357 individuals included in our study were diagnosed with diabetes. Among these, 18,751,659 diabetes patients were identified as medication users, with 1,058,686 (5.7 %) of them taking SGLT2 inhibitors. Over the 7-year study period, the percentage of patients taking SGLT2 inhibitors increased 21-fold, from 0.4 % in 2013–2014 to 9.4 % in 2017–2020. Despite this substantial increase, the utilization of other second-line antidiabetic agents, such as sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, and TZDs, remained relatively stable during the same period.

Conclusions

SGLT2 inhibitor utilization has significantly increased among US diabetes patients; however, their rise has not substantially impacted the use of other second-line antidiabetic agents. Further research is needed to understand the social determinants and potential barriers affecting the broader adoption of these beneficial medications.

中文翻译：

---

一项全国代表性调查中 SLGT2 抑制剂在糖尿病患者中的使用和影响：2013-2020 年 NHANES 的调查结果

背景和目标

本研究的目的是调查2013 年引入 SGLT2 抑制剂后，具有全国代表性的美国人口样本中抗糖尿病药物的使用模式。

方法

该研究利用 2013 年至 2020 年国家健康和营养检查调查 (NHANES) 数据来确定使用抗糖尿病药物的成年糖尿病患者。随着时间的推移，绘制了使用不同抗糖尿病药物（包括 SGLT2 抑制剂）的糖尿病患者比例。为了评估 SGLT2 抑制剂和其他口服降糖药使用趋势的统计显着性，采用逻辑回归模型。

结果

我们的研究中总共有 26,421,357 人被诊断患有糖尿病。其中，18,751,659 名糖尿病患者被确定为药物使用者，其中 1,058,686 名（5.7%）正在服用 SGLT2 抑制剂。在为期 7 年的研究期间，服用 SGLT2 抑制剂的患者比例增加了 21 倍，从 2013-2014 年的 0.4% 增加到 2017-2020 年的 9.4%。尽管大幅增加，其他二线抗糖尿病药物（如磺酰脲类、DPP-4 抑制剂、GLP-1 受体激动剂和 TZD）的使用在同一时期仍保持相对稳定。

结论

美国糖尿病患者中 SGLT2 抑制剂的使用率显着增加；然而，它们的增加并没有实质性影响其他二线抗糖尿病药物的使用。需要进一步的研究来了解影响这些有益药物更广泛采用的社会决定因素和潜在障碍。